Zhang Investor Law Reminds Investors of September 23 Deadline in Securities Class Action Lawsuit Against Karyopharm Therapeutics Inc. – KPTI
NEW YORK, NY / ACCESSWIRE / September 13, 2019 / Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) from March 2, 2017 through February 22, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Karyopharm investors under the federal securities laws.
If you wish to serve as lead plaintiff, you must move the Court no later than September 23, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to obtain a recovery is not dependent upon being a lead plaintiff. If you wish to join the http://zhanginvestorlaw.com/join-action-form/?slug=karyopharm-therapeutics-inc&id=1958 or to discuss your rights or interests regarding this class action, please contact Sophie Zhang, Esq. or Spencer Lee toll-free at 800-991-3756 or email firstname.lastname@example.org, email@example.com for information on the class action.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) data from the Phase 2 SOPRA trial (“SOPRA”) demonstrated that the Company’s lead drug candidate, selinexor, was associated with significant toxicity, was not well-tolerated among patients with AML, and resulted in a higher risk of death; (2) patients experienced serious drug-related side effects, with eighty percent of the AML patients treated with selinexor trial experiencing a serious adverse event; (3) as a result, nearly half of the acute myeloid leukemia (“AML”) patients were forced to withdraw from the SOPRA trial because of drug-related toxicity (4) in addition, the toxicity profile of selinexor for the treatment of patients with multiple myeloma in Part 2 of the Phase 2b STORM study was similar to that observed in AML patients treated with selinexor in the SOPRA study; and (5) as a result, Karyopharm’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class has not been certified. You may retain counsel of your choice. You may take no action at this time and be an absent class member. Your ability to obtain a recovery is not dependent upon being a lead plaintiff.
Zhang Investor Law represents investors worldwide. Attorney Advertising. Prior results do not guarantee similar outcomes.
Zhang Investor Law P.C.
99 Wall Street, Suite 232
New York, New York 10005
tel: (800) 991-3756
SOURCE: Zhang Investor Law P.C.